234 related articles for article (PubMed ID: 36768563)
1. In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part III.
Witkowski J; Polak S; Pawelec D; Rogulski Z
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768563
[TBL] [Abstract][Full Text] [Related]
2. In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part II.
Witkowski J; Polak S; Rogulski Z; Pawelec D
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233247
[TBL] [Abstract][Full Text] [Related]
3. In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part I.
Witkowski J; Polak S; Rogulski Z; Pawelec D
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361773
[TBL] [Abstract][Full Text] [Related]
4. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen.
Loisios-Konstantinidis I; Cristofoletti R; Jamei M; Turner D; Dressman J
Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33147873
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous Ivabradine Parent-Metabolite PBPK/PD Modelling Using a Bayesian Estimation Method.
Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
AAPS J; 2020 Oct; 22(6):129. PubMed ID: 33033962
[TBL] [Abstract][Full Text] [Related]
6. Physiologically-based pharmacokinetic/pharmacodynamic modeling to predict tumor growth inhibition and the efficacious dose of selective estrogen receptor degraders in humans.
Ganti A; Yu S; Sharpnack D; Ingalla E; De Bruyn T
Biopharm Drug Dispos; 2023 Aug; 44(4):301-314. PubMed ID: 37102506
[TBL] [Abstract][Full Text] [Related]
7. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.
Rostami-Hodjegan A
Clin Pharmacol Ther; 2012 Jul; 92(1):50-61. PubMed ID: 22644330
[TBL] [Abstract][Full Text] [Related]
8. DallphinAtoM: Physiologically based pharmacokinetics software predicting human PK parameters based on physicochemical properties, in vitro and animal in vivo data.
Choi S; Han S; Lee SJ; Lim B; Bae SH; Han S; Yim DS
Comput Methods Programs Biomed; 2022 Apr; 216():106662. PubMed ID: 35151112
[TBL] [Abstract][Full Text] [Related]
9. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma.
Kim HY; Upadhyay PJ; Fahmy A; Liu X; Duong JK; Boddy AV
Clin Pharmacokinet; 2019 Aug; 58(8):1029-1043. PubMed ID: 30868471
[TBL] [Abstract][Full Text] [Related]
10. Physiologically based pharmacokinetic/pharmacodynamic modeling to evaluate the absorption of midazolam rectal gel.
Zhu J; Zhao Y; Wang L; Zhou C; Zhou S; Chen T; Chen J; Zhang Z; Zhu Y; Ding S; Shao F
Eur J Pharm Sci; 2021 Dec; 167():106006. PubMed ID: 34520836
[TBL] [Abstract][Full Text] [Related]
11. Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study.
Yoon M; Kedderis GL; Yan GZ; Clewell HJ
Toxicology; 2015 Jun; 332():52-66. PubMed ID: 24863738
[TBL] [Abstract][Full Text] [Related]
12. Physiologically Based Pharmacokinetic Model for Older Adults and Its Application in Geriatric Drug Research.
Wu X; Sia JEV; Hai M; Lai X; Li H; Cui C; Liu D
Curr Drug Metab; 2023; 24(3):211-222. PubMed ID: 37165496
[TBL] [Abstract][Full Text] [Related]
13. Physiologically-based PK/PD modelling of therapeutic macromolecules.
Thygesen P; Macheras P; Van Peer A
Pharm Res; 2009 Dec; 26(12):2543-50. PubMed ID: 19847627
[TBL] [Abstract][Full Text] [Related]
14. Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes.
Chenel M; Bouzom F; Aarons L; Ogungbenro K
J Pharmacokinet Pharmacodyn; 2008 Dec; 35(6):635-59. PubMed ID: 19130188
[TBL] [Abstract][Full Text] [Related]
15. Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.
Thai HT; Mazuir F; Cartot-Cotton S; Veyrat-Follet C
Br J Clin Pharmacol; 2015 Sep; 80(3):534-47. PubMed ID: 26095234
[TBL] [Abstract][Full Text] [Related]
16. Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation.
Pierrillas PB; Henin E; Ogier J; Amiel M; Kraus-Berthier L; Chenel M; Bouzom F; Tod M
Invest New Drugs; 2020 Dec; 38(6):1796-1806. PubMed ID: 32451663
[TBL] [Abstract][Full Text] [Related]
17. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
[TBL] [Abstract][Full Text] [Related]
18. Physiologically based pharmacokinetic combined JAK2 occupancy modelling to simulate PK and PD of baricitinib with kidney transporter inhibitors and in patients with hepatic/renal impairment.
Wang Z; Liu W; Li X; Chen H; Qi D; Pan F; Liu H; Yu S; Yi B; Wang G; Liu Y
Regul Toxicol Pharmacol; 2022 Aug; 133():105210. PubMed ID: 35700864
[TBL] [Abstract][Full Text] [Related]
19. Development and Qualification of a Physiologically Based Pharmacokinetic Model of Finasteride and Minoxidil Following Scalp Application.
Ngampanya A; Udomnilobol U; Sermsappasuk P; Pornputtapong N; Ongpipattanakul B; Patel N; Jianmongkol S; Prueksaritanont T
J Pharm Sci; 2021 May; 110(5):2301-2310. PubMed ID: 33609522
[TBL] [Abstract][Full Text] [Related]
20. Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma.
Homet Moreno B; Mok S; Comin-Anduix B; Hu-Lieskovan S; Ribas A
Oncoimmunology; 2016 Jul; 5(7):e1052212. PubMed ID: 27622011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
